Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Innovative Point of Care for combined screening of Infectious diseases: application to Prevention of Mother to Child Transmission

Descrizione del progetto

Migliorare la diagnosi delle infezioni letali nell’Africa subsahariana

Nell’Africa subsahariana (ASS), la sotto-diagnosi delle infezioni da HIV e da epatite virale rimane una sfida. I dati mostrano 4,5 milioni di nuove infezioni all’anno e 1,8 milioni di decessi a livello globale. Essi sono spesso legati alla trasmissione da madre a figlio e alla complessità degli algoritmi diagnostici per le donne incinte affette da epatite B. Per affrontare questo problema, il progetto MAGFA, finanziato dall’UE, svilupperà un dispositivo nomade decentrato in grado di eseguire da 4 a 8 analisi immunitarie in meno di 15 minuti. Il pannello di test iniziale sarà mirato all’HIV e alle epatiti virali B e C. Inoltre, includerà un test di screening della sifilide e un test di conferma dell’HBV per orientare le donne in gravidanza verso un trattamento profilattico a sostegno di un programma di tripla eliminazione tra le donne in gravidanza.

Obiettivo

By essence, diagnostic procedures intend to look for a certain panel of pathologies according to the risk factors or the symptoms of the patients to prevent further contaminations. This approach is particularly crucial in the context of concomitant epidemics affecting the same kind of populations such as HIV and Viral Hepatitis and Syphilis.
Despite the huge effort made on HIV diagnostics, its main co-infections Viral Hepatitis and Syphilis has been widely ignored, particularly in SSA where less than 95% of infected people know their status (WHO 2021). Such underdiagnosis lead 4,5m new infections yearly over the world, and 1,8m deaths with at least 32% occurring in SSA.
Those new infections in SSA are mainly due mother-to-child transmission, due to insufficient combined testing of pregnant women. The other cause is due to the present complexity of the testing algorithm to orient HBV pregnant women with active viremia toward treatment.
A fully portable, autonomous multiplexed Point of Care device (3kg, 8h autonomy) has been developed. It is capable to perform 4 to 8 immuno-analyses in parallel in less than 15mn filing using 50µL of capillary blood. A first panel has been developed targeting HIV 1 & 2, Viral Hepatitis B and C.
The goal of this project is first to evaluate the kit in SSA to see how the technology behave in different environments (Temperature, Humidity) and with blood presenting multiple other infections.
MagIA IBC solution will be thus evaluated in lab and in the field among pregnant women to assess the performance and its impact on the Prevention of Mother To Child Transmission (PMTCT) particularly in region with low HIV prevalence where no testing is performed at all.
Meanwhile a syphilis screening assay will be implemented and evaluated to better meet WHO Triple Elimination screening. ALAT and HBe-Ag assay will be developed to propose a Test and Treat approach for Hep B and further decrease mother to child transmission of Hepatitis B.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-JU-GH-EDCTP3-2023-02-two-stage

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

MAGIA DIAGNOSTICS
Contributo netto dell'UE
€ 1 958 341,25
Indirizzo
15 RUE MARECHAL LECLERC
38130 ECHIROLLES
Francia
Regione
Auvergne-Rhône-Alpes Rhône-Alpes Isère
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 1 958 341,25

Partecipanti (6)